Results for tag: "Hypofibrinogenemia Drug"

Hypofibrinogenemia is a rare hematological disorder characterized by a deficiency of fibrinogen, a protein involved in the clotting of blood. Treatment of hypofibrinogenemia typically involves the administration of fibrinogen concentrate, a drug that helps to restore the body's normal clotting ability. The hypofibrinogenemia drug market is a small but growing segment of the hematological drugs market. It is driven by the increasing prevalence of hypofibrinogenemia, as well as the development of new treatments and therapies. The market is expected to grow at a steady rate over the next few years, driven by the increasing demand for fibrinogen concentrate and other treatments. Some of the major companies in the hypofibrinogenemia drug market include CSL Behring, Grifols, Octapharma, Kedrion, and Shire. These companies are engaged in the development, manufacture, and marketing of fibrinogen concentrate and other treatments for hypofibrinogenemia. Show Less Read more